Drug–Drug, Drug–Disease and Disease–Disease Interactions in COVID-19 with Cardiovascular Diseases (CVDs)

Drug–Drug, Drug–Disease and Disease–Disease Interactions in COVID-19 with Cardiovascular Diseases (CVDs)

Coronaviruses are a large family of single positive-stranded, enveloped RNA viruses that can infect many animal species and humans. Human coronaviruses can be divided based on their pathogenicity. Globally so far, over nine million people have tested COVID-19 positive, of which, 4, 25,000 are in Ind...

Full description

Bibliographic Details
Main Authors: M. Jyotsna, Y. Hemalatha
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2020-09-01
Series:Indian Journal of Cardiovascular Disease in Women
Subjects:
cardiovascular drugs
covid-drugs
interactions
pharmacotherapies
Online Access:http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1716786
id doaj-225c46bf0662496889970309937f8ec5
record_format Article
spelling doaj-225c46bf0662496889970309937f8ec52020-12-02T18:29:25ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Cardiovascular Disease in Women2455-78542020-09-0150321622210.1055/s-0040-1716786Drug–Drug, Drug–Disease and Disease–Disease Interactions in COVID-19 with Cardiovascular Diseases (CVDs)M. Jyotsna0Y. Hemalatha1Department of Cardiology, Nizams Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, IndiaDepartment of Cardiology, Nizams Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, IndiaCoronaviruses are a large family of single positive-stranded, enveloped RNA viruses that can infect many animal species and humans. Human coronaviruses can be divided based on their pathogenicity. Globally so far, over nine million people have tested COVID-19 positive, of which, 4, 25,000 are in India. The FDA for the prevention or treatment of COVID-19 has approved no drugs or biologics. Numerous other antiviral agents, immunotherapies, and vaccines continue to be investigated and developed as potential therapies. Searching for effective therapies for COVID-19 infection is a complex process. The cardiovascular disease (CVD) drugs and the COVID-19 treating drugs show potent drug–drug interactions (DDI), disease–drug interactions, and disease–disease interactions.http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1716786cardiovascular drugscovid-drugsinteractionspharmacotherapies
collection DOAJ
language English
format Article
sources DOAJ
author M. Jyotsna
Y. Hemalatha
spellingShingle M. Jyotsna
Y. Hemalatha
Drug–Drug, Drug–Disease and Disease–Disease Interactions in COVID-19 with Cardiovascular Diseases (CVDs)
Indian Journal of Cardiovascular Disease in Women
cardiovascular drugs
covid-drugs
interactions
pharmacotherapies
author_facet M. Jyotsna
Y. Hemalatha
author_sort M. Jyotsna
title Drug–Drug, Drug–Disease and Disease–Disease Interactions in COVID-19 with Cardiovascular Diseases (CVDs)
title_short Drug–Drug, Drug–Disease and Disease–Disease Interactions in COVID-19 with Cardiovascular Diseases (CVDs)
title_full Drug–Drug, Drug–Disease and Disease–Disease Interactions in COVID-19 with Cardiovascular Diseases (CVDs)
title_fullStr Drug–Drug, Drug–Disease and Disease–Disease Interactions in COVID-19 with Cardiovascular Diseases (CVDs)
title_full_unstemmed Drug–Drug, Drug–Disease and Disease–Disease Interactions in COVID-19 with Cardiovascular Diseases (CVDs)
title_sort drug–drug, drug–disease and disease–disease interactions in covid-19 with cardiovascular diseases (cvds)
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
series Indian Journal of Cardiovascular Disease in Women
issn 2455-7854
publishDate 2020-09-01
description Coronaviruses are a large family of single positive-stranded, enveloped RNA viruses that can infect many animal species and humans. Human coronaviruses can be divided based on their pathogenicity. Globally so far, over nine million people have tested COVID-19 positive, of which, 4, 25,000 are in India. The FDA for the prevention or treatment of COVID-19 has approved no drugs or biologics. Numerous other antiviral agents, immunotherapies, and vaccines continue to be investigated and developed as potential therapies. Searching for effective therapies for COVID-19 infection is a complex process. The cardiovascular disease (CVD) drugs and the COVID-19 treating drugs show potent drug–drug interactions (DDI), disease–drug interactions, and disease–disease interactions.
topic cardiovascular drugs
covid-drugs
interactions
pharmacotherapies
url http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1716786
work_keys_str_mv AT mjyotsna drugdrugdrugdiseaseanddiseasediseaseinteractionsincovid19withcardiovasculardiseasescvds
AT yhemalatha drugdrugdrugdiseaseanddiseasediseaseinteractionsincovid19withcardiovasculardiseasescvds
_version_ 1724403916593954816

Similar Items